Cogstate Limited Stock price

Equities

CGS

AU000000CGS8

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
1.35 AUD +5.47% Intraday chart for Cogstate Limited +4.65% -6.57%
Sales 2024 * 64.05M 41.81M Sales 2025 * 78.57M 51.28M Capitalization 231M 151M
Net income 2024 * 5M 3.26M Net income 2025 * 6M 3.92M EV / Sales 2024 * 3.03 x
Net cash position 2024 * 36.99M 24.15M Net cash position 2025 * 40.36M 26.34M EV / Sales 2025 * 2.43 x
P/E ratio 2024 *
44.2 x
P/E ratio 2025 *
35.3 x
Employees 158
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.47%
1 week+4.65%
Current month+8.00%
1 month+8.00%
3 months-9.09%
6 months-11.48%
Current year-6.57%
More quotes
1 week
1.26
Extreme 1.26
1.35
1 month
1.13
Extreme 1.125
1.35
Current year
1.13
Extreme 1.125
1.48
1 year
1.13
Extreme 1.125
1.87
3 years
0.80
Extreme 0.8
2.68
5 years
0.16
Extreme 0.155
2.68
10 years
0.14
Extreme 0.14
2.68
More quotes
Managers TitleAgeSince
Founder - 99-12-16
Chief Executive Officer - 04-04-30
Director of Finance/CFO - 21-01-31
Members of the board TitleAgeSince
Chairman 65 -
Director/Board Member 57 10-08-25
Director/Board Member 50 19-08-28
More insiders
Date Price Change Volume
24-03-28 1.35 +5.47% 124,371
24-03-27 1.28 -2.29% 73,390
24-03-26 1.31 +2.34% 140,557
24-03-25 1.28 -1.16% 59,053
24-03-22 1.295 +0.39% 63,590

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
Cogstate Ltd is a neuroscience technology company. It is engaged in the creation, validation, and commercialization of digital brain health assessments and design and assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Research. The Clinical Trials segment includes adoption of decentralized clinical trial methodologies and scientific publication and marketing of the utility and validity of Cogstate technology. The Healthcare segment includes Cognigram, which allows for regular and standardized testing to assist in the early detection of cognitive decline that could be related to a range of factors including head injury, neurodegenerative disease or side effects following pharmacological treatments. The Research segment includes research studies and academic collaborations across various indications, such as Alzheimer's disease and Parkinson's disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.35 AUD
Average target price
1.8 AUD
Spread / Average Target
+33.33%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Cogstate Limited - Australian S.E.